Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immuneering Corporation stock logo
IMRX
Immuneering
$5.99
+4.2%
$3.96
$1.10
$6.35
$217.55M0.431.24 million shs879,495 shs
MariMed Inc. stock logo
MRMD
MariMed
$0.18
+16.9%
$0.10
$0.07
$0.20
$70.28M3627,828 shs5.74 million shs
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$11.87
+4.3%
$10.35
$5.67
$26.56
$196.33M-0.1110,036 shs34,459 shs
Instil Bio, Inc. stock logo
TIL
Instil Bio
$29.22
+8.2%
$26.47
$10.80
$92.00
$197.24M2.16189,234 shs107,381 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%-3.36%+70.62%+193.37%+418.02%
MariMed Inc. stock logo
MRMD
MariMed
0.00%+33.91%+57.95%+110.10%-16.98%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
0.00%+4.60%+8.48%+43.98%-30.78%
Instil Bio, Inc. stock logo
TIL
Instil Bio
0.00%+5.02%+21.46%-9.70%+93.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immuneering Corporation stock logo
IMRX
Immuneering
2.959 of 5 stars
3.32.00.00.01.95.00.6
MariMed Inc. stock logo
MRMD
MariMed
0.3967 of 5 stars
0.03.00.00.02.80.80.0
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
4.2057 of 5 stars
4.32.00.04.21.61.70.6
Instil Bio, Inc. stock logo
TIL
Instil Bio
3.5706 of 5 stars
3.54.00.00.03.33.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.00117.03% Upside
MariMed Inc. stock logo
MRMD
MariMed
4.00
Strong BuyN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.50
Moderate Buy$21.5781.73% Upside
Instil Bio, Inc. stock logo
TIL
Instil Bio
3.00
Buy$119.00307.26% Upside

Current Analyst Ratings Breakdown

Latest MRMD, TIL, IMRX, and RAPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00 ➝ $125.00
8/26/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
8/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/15/2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00 ➝ $125.00
8/14/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
8/13/2025
MariMed Inc. stock logo
MRMD
MariMed
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/12/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$8.00 ➝ $9.00
8/8/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$51.00 ➝ $38.00
7/30/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$14.00
7/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$31.00
7/10/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00
(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/A$1.33 per shareN/A
MariMed Inc. stock logo
MRMD
MariMed
$157.96M0.44$0.03 per share7.14$0.16 per share1.13
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$1.53M128.32N/AN/A$11.51 per share1.03
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/A$25.96 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)
MariMed Inc. stock logo
MRMD
MariMed
-$12.16M-$0.03N/AN/A-10.14%-10.52%-3.10%11/5/2025 (Estimated)
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%11/11/2025 (Estimated)
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$74.14M-$12.92N/AN/AN/AN/A-54.32%-33.65%11/12/2025 (Estimated)

Latest MRMD, TIL, IMRX, and RAPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.40-$0.40N/A-$0.40N/AN/A
8/13/2025Q2 2025
Instil Bio, Inc. stock logo
TIL
Instil Bio
-$1.72-$3.24-$1.52-$3.24N/AN/A
8/7/2025Q2 2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$0.61-$0.65-$0.04-$0.65N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
MariMed Inc. stock logo
MRMD
MariMed
N/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/AN/A
Instil Bio, Inc. stock logo
TIL
Instil Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
3.70
3.70
MariMed Inc. stock logo
MRMD
MariMed
1.25
1.12
0.36
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/A
13.25
13.25
Instil Bio, Inc. stock logo
TIL
Instil Bio
0.64
14.97
14.97

Institutional Ownership

CompanyInstitutional Ownership
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
MariMed Inc. stock logo
MRMD
MariMed
0.18%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
99.09%
Instil Bio, Inc. stock logo
TIL
Instil Bio
60.56%

Insider Ownership

CompanyInsider Ownership
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
MariMed Inc. stock logo
MRMD
MariMed
18.99%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
6.60%
Instil Bio, Inc. stock logo
TIL
Instil Bio
46.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immuneering Corporation stock logo
IMRX
Immuneering
6036.32 million28.00 millionNot Optionable
MariMed Inc. stock logo
MRMD
MariMed
260390.43 million316.29 millionNot Optionable
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
8016.54 million15.45 millionOptionable
Instil Bio, Inc. stock logo
TIL
Instil Bio
4106.75 million3.61 millionNo Data

Recent News About These Companies

Instil Bio Reports Promising Phase 2 Study Results
Instil Bio appoints new Chief Medical Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Immuneering stock logo

Immuneering NASDAQ:IMRX

$5.99 +0.24 (+4.17%)
Closing price 04:00 PM Eastern
Extended Trading
$5.99 0.00 (-0.02%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

MariMed stock logo

MariMed OTCMKTS:MRMD

$0.18 +0.03 (+16.88%)
As of 03:59 PM Eastern

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Rapt Therapeutics stock logo

Rapt Therapeutics NASDAQ:RAPT

$11.87 +0.49 (+4.31%)
Closing price 04:00 PM Eastern
Extended Trading
$11.96 +0.09 (+0.76%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Instil Bio stock logo

Instil Bio NASDAQ:TIL

$29.22 +2.22 (+8.22%)
Closing price 04:00 PM Eastern
Extended Trading
$29.28 +0.05 (+0.19%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.